Abstract
Since the first descriptions of chronic recurrent multifocal osteomyelitis in the 1970s, there have been numerous case reports in the literature; both unusual case reports and case series from all over the world. Our understanding of the pathogenesis has significantly changed, with it now being regarded as an autoinflammatory condition. Treatment options have also expanded, but little progress has been made in developing the evidence for treatments. Advancing gene studies have provided a mouse model, but the quest for a single gene to match the phenotype has been elusive. Early cohorts of patients have grown up into adults, allowing prospective data to inform the expected outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 41-48 |
| Number of pages | 8 |
| Journal | Rheumatology |
| Volume | 57 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Bibliographical note
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected].Keywords
- Adult
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Antirheumatic Agents/therapeutic use
- Autoimmune Diseases/diagnostic imaging
- Biological Products/therapeutic use
- Bone Density Conservation Agents/therapeutic use
- Child
- Diphosphonates/therapeutic use
- Disease Models, Animal
- Glucocorticoids/therapeutic use
- Humans
- Immunity, Innate/immunology
- Inflammation/diagnostic imaging
- Magnetic Resonance Imaging
- Mice
- Osteomyelitis/diagnostic imaging
- Whole Body Imaging